Sign in

    Chad Messer • Needham & Company

    Chad Messer, Ph.D., most recently served as Senior Research Analyst specializing in biotechnology within the healthcare sector at Needham & Company, where he covered a range of public biotech firms including Sarepta Therapeutics, ArQule, Gamida Cell, and others. Over his tenure, he issued over 270 stock ratings with a 47.5% price target met ratio, an average potential upside of 48%, and notable high-performance calls such as a 44.8% return on Sarepta within five days. Messer joined Needham in 2012 after equity research roles at Piper Jaffray and Paramount Biocapital, as well as corporate development experience at Genaissance Pharmaceuticals, and continued as a senior life sciences analyst for over 15 years before taking on investor relations at Cullinan Therapeutics and then joining Lake Street Capital in 2025. He holds a Ph.D. in Pharmacology from Yale, an MBA from NYU’s Stern School of Business, and maintains FINRA registration with Series 7 and 63 licenses.

    Chad Messer's questions to Lantern Pharma Inc (LTRN) leadership

    Chad Messer's questions to Lantern Pharma Inc (LTRN) leadership • Q1 2025

    Question

    Chad Messer of Needham & Company inquired about Lantern's commercialization strategy for its RADR AI modules and sought clarification on the design of the Harmonic trial for LP-300, particularly regarding the enrollment of Asian patients.

    Answer

    Panna Sharma, an executive at Lantern Pharma, explained that the RADR AI modules will initially launch with a freemium model to drive collaborations and tech partnerships, while the company's primary focus remains on its internal pipeline. Regarding the Harmonic trial, Sharma clarified that after a successful U.S. lead-in cohort, the trial has moved to a randomized expansion phase that includes both U.S. and Asian patients, rather than a separate 'Asian cohort'.

    Ask Fintool Equity Research AI